Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Baseline Optical Coherence Tomography Biomarkers Associated with the 2-Year Development of Macular Atrophy or Fibrosis in Neovascular Age-related Macular Degeneration.

Ophthalmology science·2026
Same author

Switching to aflibercept 8 mg in neovascular age-related macular degeneration: real-world outcomes according to switch indication.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026
Same author

Vision-related quality of life in non-neovascular age-related macular degeneration: a protocol for systematic review and meta-analysis.

Eye (London, England)·2026
Same author

Review of emerging imaging findings to reveal a broader spectrum of lesions in AMD.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026
Same author

Peripapillary pachychoroid syndrome: Clinical and imaging features, diagnostic differentiation and therapeutic strategies.

Survey of ophthalmology·2026
Same author

Faricimab: current evidence for the treatment of retinal vein occlusion.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026

Related Experiment Video

Updated: Apr 28, 2026

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
10:14

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

4.1K

Changes in macular function after ozurdex for retinal vein occlusion.

Giuseppe Querques1, Maria Lucia Cascavilla, Edoardo Cavallero

  • 1*MD, PhD †MD ‡MD, FEBO Department of Ophthalmology, University Scientific Institute San Raffaele, Milan, Italy (all authors); and Department of Ophthalmology, University Paris Est Creteil, Centre Hospitalier Intercommunal de Creteil, Creteil, France (GQ).

Optometry and Vision Science : Official Publication of the American Academy of Optometry
|June 14, 2014
PubMed
Summary

Intravitreal dexamethasone implant (Ozurdex) improves vision and macular function in retinal vein occlusion (RVO) patients within one month. Optimal retreatment for macular edema (ME) is typically under six months, with baseline sensitivity predicting need.

More Related Videos

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability
07:23

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability

Published on: August 6, 2021

2.7K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.7K

Related Experiment Videos

Last Updated: Apr 28, 2026

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
10:14

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

4.1K
Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability
07:23

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability

Published on: August 6, 2021

2.7K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.7K

Area of Science:

  • Ophthalmology
  • Retinal Diseases
  • Pharmacology

Background:

  • Macular edema (ME) secondary to retinal vein occlusion (RVO) significantly impairs visual function.
  • Intravitreal corticosteroid injections are a common treatment for ME.

Purpose of the Study:

  • To assess the functional and morphological changes in the macula following intravitreal dexamethasone implant (Ozurdex) for ME in RVO patients.
  • To correlate functional outcomes with morphological parameters.

Main Methods:

  • Nineteen treatment-naive RVO patients with ME received intravitreal Ozurdex.
  • Functional outcomes (visual acuity, microperimetry, multifocal electroretinography) and morphological parameters (OCT) were evaluated up to 6 months.
  • Correlations between functional and morphological data were analyzed.

Main Results:

  • Significant improvements in best-corrected visual acuity, retinal sensitivity, and reduced central macular thickness (CMT) were observed at 1 month post-injection (p<0.05).
  • Functional and morphological improvements persisted at 3 months but were not significant from month 4 onwards.
  • A negative correlation between CMT and retinal sensitivity was noted; better baseline sensitivity predicted less frequent retreatment.

Conclusions:

  • Intravitreal Ozurdex offers functional benefits for ME secondary to RVO, with improvements noted as early as 1 month.
  • The optimal retreatment interval for Ozurdex in RVO-related ME is generally less than 6 months.
  • Microperimetry is valuable for assessing macular function, and baseline sensitivity can predict retreatment needs.